← Back to patent-cliff list
Bemnifosbuvir
Tier C — Watch / tradeBemnifosbuvir
Atea Pharmaceuticals Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Nucleic acid drug
Type
Targets：NS5B, RdRp
Indications (approved)：Hepatitis C, COVID-19, Liver cirrhosis, Chronic hepatitis C, Hepatic function decline, Renal impairment
Regional status
US
Phase III
2022-11-25
EU
Phase III
2021-04-28
China
-
Japan
Phase III
2021-04-28
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Bemnifosbuvir?
Approved indications include: Hepatitis C, COVID-19, Liver cirrhosis, Chronic hepatitis C, Hepatic function decline, Renal impairment.
When does the Bemnifosbuvir patent expire?
No public expiry year is available for Bemnifosbuvir yet; this page updates once verified.
How do I get a quote for Bemnifosbuvir intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06